Pressreleaser | 17 Mar 2023 | Scandinavian Chemotech

Scandinavian ChemoTech participates and presents at the LSI Emerging Medtech Summit in California, USA

The conference is an event where ChemoTech and other medical device companies will present their innovations to some of the biggest players and investors in the medtech field. Participants include Medtronic, Johnson & Johnson and Boston Scientific as well as representatives from institutional investors and Family Offices.

The event is seen as an important step in ChemoTech’s ambitions to find global strategic alliances in areas such as robotic surgery or laparoscopy and to find strategic and long-term investors.

LSI Emerging Market Summit 2023 takes place between March 20 and 23 in Dana Point, California. More information about the conference is available at the link below:

LSI Medtech Summit 2023 ( https://www.lifesciencemarketresearch.com/medtech-summit-2023 )

For further information please contact:

Mohan Frick, CEO

Phone: +46 (0)10-218 93 00

E-mail: ir@chemotech.se

Scandinavian ChemoTech AB (publ)

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech’s shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Redeye AB is the company’s Certified Adviser. Read more at: www.chemotech.se.